Blood and Marrow Transplant Handbook : (Record no. 67741)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11094nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC3109874 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729124509.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2015 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783319138329 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9783319138312 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC3109874 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL3109874 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11048043 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL790162 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)936335776 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RD120.6-129.8 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Maziarz, Richard T. |
| 245 10 - TITLE STATEMENT | |
| Title | Blood and Marrow Transplant Handbook : |
| Remainder of title | Comprehensive Guide for Patient Care. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 2nd ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Cham : |
| Name of producer, publisher, distributor, manufacturer | Springer International Publishing AG, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2015. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2015. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (437 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Introduction and Acknowledgments -- Contents -- Contributors -- Part I -- The Nuts and Bolts of Stem Cell Transplantation -- Chapter-1 -- Overview of Hematopoietic Stem Cell Transplantation -- 1.1 Key Principles -- 1.2 Research Efforts in HSCT -- 1.3 Horizons/Challenges -- Bibliography -- Chapter-2 -- The Business of Cellular Therapy and Hematopoietic Stem Cell Transplantation -- 2.1 Increase in Utilization and Impact of HSCT on National Health-Care Costs -- 2.2 Complexity of Care Increases Costs -- 2.3 Contracts and Reimbursement Strategies -- 2.4 Integrated Structure for Contract Management -- 2.5 Payer Types -- 2.6 Quality -- 2.7 Clinical Trials -- 2.8 Future Considerations -- 2.9 Summary -- Bibliography -- Chapter-3 -- Hematopoietic Stem Cell Sources and Donor Selection -- 3.1 Introduction -- 3.2 Stem Cell Sources -- 3.3 Peripheral Blood -- 3.4 Umbilical Cord Blood -- 3.5 Donor Selection -- 3.6 Other Considerations -- 3.7 Donor Complications -- Bibliography -- Chapter-4 -- Pre-transplant Medical Evaluation -- 4.1 Considerations and/or Indications for Transplant -- 4.2 Sources of Hematopoietic Stem Cells -- 4.3 Patient Evaluation -- 4.4 General Guidelines for Patient Eligibility -- 4.5 Allogeneic Donor Evaluation -- Bibliography -- Chapter-5 -- Social Work: Evaluation and Support -- 5.1 Psychosocial Evaluation and Assessment -- 5.2 Preparation and Planning -- 5.3 Active Treatment: Inpatient and Outpatient -- 5.4 Immediate Short Term -- 5.5 Long Term/Survivorship -- 5.6 End-of-Life Care -- 5.7 Palliative Care and Hematologic Malignancy -- 5.8 Caregiving Needs and Requirements -- 5.9 Psychosocial Impact of Caregiving and Protective Factors -- Bibliography -- Chapter-6 -- Conditioning Regimens -- 6.1 Conditioning Agents -- Bibliography -- Chapter-7 -- Nutrition -- 7.1 Low-Bacteria Diet -- 7.2 GVHD Diet. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 7.3 Goals of Nutrition During HSCT -- 7.4 Use of TPN -- 7.5 Use of EN -- 7.6 Catabolic/Anabolic States -- 7.7 Discussion of Glutamine Controversy -- Bibliography -- Chapter-8 -- Physical and Occupational Therapy -- 8.1 Benefits of Physical Exercise -- 8.2 Areas of Consideration -- 8.3 The Role of Rehabilitation Services -- Conclusion -- References -- Chapter-9 -- Adolescent and Young Adult Concerns -- 9.1 Medical -- 9.2 Emotional -- 9.3 Physical -- 9.4 Neurocognitive -- 9.5 Social -- 9.6 Reproductive -- 9.7 Financial -- 9.8 Lifestyle Issues -- 9.9 Late Effects -- 9.10 Care Community -- 9.11 AYA-Specific Resources -- Bibliography -- Chapter-10 -- Infection Prophylaxis -- 10.1 Herpes Simplex Virus/Varicella ZosterVirus Prophylaxis -- 10.2 Cytomegalovirus Disease Prevention -- 10.3 Antibacterial Prophylaxis -- 10.4 Encapsulated Organism Prophylaxis for Patients with Chronic GVHD -- 10.5 Antifungal Prophylaxis -- 10.6 Azole Antifungal Monitoring Guidelines -- 10.7 Pneumocystis Jirovechii Prophylaxis -- 10.8 Viral Hepatitis -- Bibliography -- Chapter-11 -- Graft-Versus-Host Disease Prophylaxis -- 11.1 Standard Prophylaxis -- 11.2 New Approaches -- 11.3 Future Directions -- 11.4 Agents used for GVHD Prophylaxis -- Bibliography -- Chapter-12 -- Transfusion Medicine -- 12.1 General Transfusion Considerations -- 12.2 Peri-HSCT Considerations -- 12.3 Day 0 Transplant Infusion Considerations -- 12.4 Post-HSCT Considerations -- 12.5 Transfer Back to Community Setting -- Bibliography -- Chapter-13 -- Antithrombotic Guidelines -- 13.1 Patients on Antithrombotic Therapy -- 13.2 Antithrombotic Therapy -- 13.3 Patients Who Develop Thrombosis -- 13.4 Role of New Direct Oral Antithrombotic Agents -- Bibliography -- Chapter-14 -- Engraftment -- 14.1 Autologous -- 14.2 Allogeneic -- 14.3 Engraftment Syndrome. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 14.4 Foundation for the Accreditation of Cellular Therapy Standards for Review of Engraftment -- Bibliography -- Chapter-15 -- Follow-Up Care -- 15.1 Outpatient Follow-up -- 15.2 Immunosuppression -- 15.3 Immunizations -- 15.4 Central Venous Catheters -- 15.5 Activities of Daily Living Guidelines -- 15.6 Osteoporosis -- 15.7 Diet and Food Preparation -- 15.8 Travel Safety -- Bibliography -- Part II -- Transplant Complications and Ongoing Care -- Chapter-16 -- Radiology Pearls for the Transplant Provider -- 16.1 Chest -- 16.2 Abdomen -- Bibliography -- Chapter-17 -- Infectious Complications -- 17.1 Temporal Sequence of Infections -- 17.2 Empiric Antimicrobial Therapy and Evaluation of Neutropenic Fever -- 17.3 Treatment of Common Specific Infections in the HSCT Population -- Bibliography -- Chapter-18 -- Acute Graft-Versus-Host Disease (GVHD) -- 18.1 Pathophysiology -- 18.2 Risk Factors -- 18.3 Incidence -- 18.4 Clinical Presentation -- 18.5 Evaluation and Diagnosis -- 18.6 Staging/Grading -- 18.7 Treatment (See Chap. 11 for discussion of GVHD Prophylaxis) -- 18.8 Steroid Refractory Disease -- 18.9 Autologous GvHD -- 18.10 Conclusions -- Bibliography -- Chapter-19 -- Chronic Graft-Versus-Host Disease -- 19.1 Pathophysiology -- 19.2 Incidence -- 19.3 Risk Factors -- 19.4 Factors Associated with Decreased Survival -- 19.5 Diagnosis of cGVHD -- 19.6 Grading of cGVHD -- 19.7 Treatment of cGVHD -- 19.8 Response Assessment -- 19.9 Follow-up -- Bibliography -- Chapter-20 -- Oral Complications -- 20.1 Pathophysiology -- 20.2 Risk Factors -- 20.3 Prophylaxis -- 20.4 Infections -- 20.5 Dental Procedures -- 20.6 Taste Alterations -- 20.7 Discharge Instructions -- Bibliography -- Chapter-21 -- Gastrointestinal Complications -- 21.1 Upper Gastrointestinal -- 21.2 Lower Gastrointestinal -- 21.3 Hepatobiliary Diseases -- Bibliography -- Chapter-22. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Pulmonary Complications -- 22.1 Pulmonary Function Tests -- 22.2 Bronchoscopy -- 22.3 Diffuse Alveolar Hemorrhage -- 22.4 Idiopathic Pneumonia Syndrome -- 22.5 Bronchiolitis Obliterans Syndrome -- 22.6 Cryptogenic Organizing Pneumonia -- Bibliography -- Chapter-23 -- Cardiovascular Complications -- 23.1 Baseline Cardiac Evaluation -- 23.2 Systolic Heart Failure -- 23.3 Atrial Fibrillation -- 23.4 Cardiac Ischemia -- 23.5 Hypertension -- 23.6 Pericarditis -- 23.7 Effects of Radiation Therapy -- References -- Chapter-24 -- Kidney Disease in Hematopoietic Stem Cell Transplantation -- 24.1 Definitions of AKI and CKD -- 24.2 Kidney Disease in HSCT: Incidence and Risk -- 24.3 General Classification of Causes of AKI and Basic Evaluation -- 24.4 Timing and Cause of Renal Injury -- 24.5 Evaluation and Management of Common Causes of AKI -- 24.6 Evaluation and Management of Common Causes of CKD -- References -- Chapter-25 -- Neurologic Complications -- 25.1 Chemotherapy-Induced CNS Toxicities -- 25.2 Tremors -- 25.3 Infectious Complications (see also Chap. 17) -- 25.4 Cerebrovascular Events -- 25.5 Posterior Reversible Encephalopathy Syndrome -- 25.6 GVHD of the Central Nervous System -- Summary -- References -- Chapter-26 -- Endocrine Complications in Childhood Cancer Survivors -- 26.1 Introduction -- 26.2 Disorders of the Hypothalamic-Pituitary Axis -- 26.3 Disorders of the Thyroid Gland -- 26.4 Gonadal Dysfunction -- 26.5 Bone Health -- 26.6 Obesity and Disorders of Glucose Homeostasis -- 26.7 Recommended Tests for Screening for Late Endocrine Complications -- 26.8 Summary -- References -- Chapter-27 -- Thrombotic Microangiopathies -- 27.1 Clinical Presentation -- 27.2 Risk Factors -- 27.3 Classification -- 27.4 Etiology -- 27.5 Diagnosis -- 27.6 Treatment -- References -- Chapter-28 -- Women's Hormonal Health Issues -- 28.1 Amenorrhea -- 28.2 Contraception. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 28.3 Perimenopausal Transition and Menopause -- 28.4 Postmenopausal Hormone Replacement Therapy -- 28.5 Graft-Versus-Host Disease (see Chap. 19 for Diagnosis Criteria and Staging) -- Bibliography -- Chapter-29 -- Psychiatric Complications -- 29.1 Monitoring Mental Status -- 29.2 Delirium -- 29.3 Depression -- 29.4 Sleep Disorders -- 29.5 Drug Interactions -- 29.6 Dose Adjustments for Renal or Hepatic Impairment -- 29.7 Competence -- Bibliography -- Chapter-30 -- Graft Failure -- 30.1 Autologous HSCT -- 30.2 Allogeneic HSCT -- 30.3 Donor Leukocyte Infusion -- 30.4 Risk Factors for Graft Failure -- 30.5 Diagnosis -- 30.6 Treatment -- Bibliography -- Chapter-31 -- Secondary Malignancies -- 31.1 General Risk Factors -- 31.2 Incidence -- 31.3 Onset -- 31.4 Types of Secondary Malignancies -- 31.5 Screening and Preventive Practices -- Bibliography -- Chapter-32 -- Posttransplant Relapse -- 32.1 Relapse After Autologous HSCT -- 32.2 Relapse After Allogeneic HSCT -- 32.3 Areas of Active Research and Future Directions -- Bibliography -- Chapter-33 -- Palliative Care -- 33.1 Core Functions of Palliative Care Related to Direct Patient Care -- 33.2 Advance Care Planning -- 33.3 Support for Caregivers -- 33.4 Common HSCT-Associated Side Effects -- 33.5 Summary -- Bibliography -- Chapter-34 -- Long-Term Follow-Up and Survivorship -- 34.1 Infection (See also Chaps. 10 and 17) -- 34.2 Cardiovascular (See also Chap. 23) -- 34.3 Pulmonary (also see Chap. 22) -- 34.4 Neurologic -- 34.5 Hepatic -- 34.6 Ocular -- 34.7 Oral -- 34.8 Endocrine -- 34.9 Musculoskeletal Complications -- 34.10 Second Malignancies -- 34.11 Sexuality and Reproductive Issues (see Chap. 9) -- 34.12 Psychosocial Concerns -- Bibliography -- Appendices -- Appendix 1 -- The Vocabulary of Transplant -- Appendix 2 -- Procedure: Bone Marrow Aspirate and Biopsy -- Procedure. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Standard Tests for Marrow Studies. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Hematopoietic stem cells -- Transplantation. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Slater, Susan Schubach. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Maziarz, Richard T. |
| Title | Blood and Marrow Transplant Handbook |
| Place, publisher, and date of publication | Cham : Springer International Publishing AG,c2015 |
| International Standard Book Number | 9783319138312 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3109874">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3109874</a> |
| Public note | Click to View |
No items available.